Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a biotechnology company operating in the field of generative biology. It leverages machine learning to discover and develop novel protein therapeutics. The company's platform, called Generate Platform, integrates computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Its pipeline includes GB-0895, an investigational long-acting anti-TSLP monoclonal antibody for severe asthma intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. The company uses various protein-based modalities for drug development.

Generate Biomedicines, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol GENB. The trading currency is the US Dollar (USD), as the company is based in the United States.

Generate Biomedicines operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes and living organisms to develop products and technologies, often for medical applications. In Generate's case, it focuses on generative biology, using machine learning to design and program novel protein therapeutics for various diseases.

Generate Biomedicines is headquartered in Somerville, Massachusetts, United States. The company was incorporated in 2018 under the name Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. It operates primarily in the United States, focusing on drug discovery and development using its generative biology platform.

Generate Biomedicines' pipeline includes several notable product candidates. GB-0895 is an investigational long-acting anti-TSLP monoclonal antibody being developed for severe asthma, designed to be dosed every six months. GB-4362 is an MMAE payload neutralizer monoclonal antibody. GB-5267 is a MUC16 CAR-T cell therapy. These candidates reflect the company's use of diverse protein-based modalities, including antibodies and cell therapies, to address various therapeutic areas.